Atopic Dermatitis
Latest News
JAK inhibitor safety warnings drawn from rheumatologic data may be misleading in dermatology
The recently approved deucravacitinib is the only JAK inhibitor that has so far been exempt from these warnings.
Latest News
Study finds quality of topical steroid withdrawal videos on YouTube subpar
“We were disheartened that patient testimonial videos had the poorest quality and reliability of the information sources,” Erika McCormick said....
Latest News
Lebrikizumab monotherapy for AD found safe, effective during induction
Case Letter
Cyclosporine-Induced Posterior Reversible Encephalopathy Syndrome: An Adverse Effect in a Patient With Atopic Dermatitis
Our case highlights a rare but important adverse event associated with even low-dose cyclosporine use that should be considered in patients...
Military Dermatology
Dermatologic Implications of Sleep Deprivation in the US Military
In this article, we explore possible mechanisms by which sleep deprivation may affect the skin. We also review the potential impacts of sleep...
Latest News
How to help pediatricians apply peanut allergy guidelines
Researchers are testing whether a two-part intervention, which includes training videos and a clinical decision support tool, helps pediatricians...
Latest News
FDA expands oral JAK abrocitinib to adolescents with AD
The indication has been expanded for those aged 12-17 whose disease is not adequately controlled with other systemic drugs, including biologics,...
Latest News
Age-related atopic dermatitis phenotypes evaluated in study
“Improved understanding of the clinical phenotypes of AD may help guide choice of treatment and improve health outcomes,” the researchers wrote....
Latest News
AD outcomes improved with lebrikizumab and topical steroids
The percentage of patients who achieved the combined endpoint was more than double for the lebrikizumab plus TCS group vs. the group on TCS alone...
Latest News
AAD unveils updated guidelines for topical AD treatment in adults
Of the 12 recommendations made for adults with AD, the work group ranked 7 as “strong” based on the evidence reviewed, and the rest as “...
Latest News
Cochrane Review bolsters case that emollients don’t prevent AD
But that message is being diluted by a stream of contradictory conclusions from poor-quality systematic reviews, authors say.